A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)
Clinical trial NCT06982287 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06982287
- Sponsor
- Yong Fang
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-08-01
- Primary completion
- 2025-12-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.